Peptide Reference
Thymosin Alpha-1
Thymosin α1
A naturally occurring thymic peptide that modulates immune function. FDA-approved as Zadaxin for hepatitis B and C, and used off-label for immune support.
Status
approved
Category
immune
Typical cost
$300-600/month (Zadaxin)
Mechanism
Enhances T-cell differentiation and maturation. Increases NK cell activity. Modulates cytokine production. Restores immune balance in immunocompromised patients.
Potential benefits
- Immune enhancement
- Anti-viral support
- T-cell modulation
- FDA-approved indication
- Well-tolerated
Reported side effects
- Injection site reactions
- Rare allergic reactions
- Mild flu-like symptoms
Common dosing references
subcutaneous
1.6mg · 2x weekly
6-12 months (hepatitis)
Research notes
Zadaxin hepatitis trials
2000
FDA approval based on efficacy in hepatitis B and C
Thymosin Alpha-1 immune modulation
2009
Enhanced T-cell function and cytokine balance
Regulatory and sourcing notes
FDA-approved as Zadaxin (thymalfasin) for hepatitis B/C. Used off-label for immune modulation.
FDA-approved pharmaceutical. Requires prescription. Also available as research peptide.
Find peptide-aware clinics
Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.
Related peptides